RETRACTED: Cytoprotective effects of euxanthone against ox-LDL-induced endothelial cell injury is mediated via Nrf2
Authors: Junyu Wang
Xiaocui Bu
Yong Sun
Weijie Yu
Zhiwu Han
Shengnan Li
Journal: Life Sciences (2019)
Discipline: BIOLOGY & BIOCHEMISTRY
Keywords: Atherosclerosis; ERK; Euxanthone; Nrf2.
Affiliations: School of Pharmacy, Qingdao University, Qingdao, China; The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao, China., School of Pharmacy, Qingdao University, Qingdao, China. Electronic address: ., The Affiliated Hospital of Qingdao University, Qingdao, China., The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao, China., Qingdao Food and Drug Inspection Institute, Qingdao, China., Qingdao Central Hospital, Qingdao, China.

Abstract:  Aim: Atherosclerosis (AS) is a chronic condition of the arterial vessels and a risk factor for myocardial infarction and stroke. Euxanthone is a xanthone compound extracted from Polygala caudata, and shows vasodilatory action. The aim of this study was to determine the potential pharmacological effects of euxanthone against oxidized low-density lipoprotein (ox-LDL)-induced endothelial cell injury. Material and methods: Human umbilical vein endothelial cells (HUVECs) were exposed to ox-LDL, following pre-treatment with different concentrations of euxanthone. Viability, apoptosis and DNA fragmentation were respectively assessed by CCK-8 assay, Annexin-V/PI staining and TdT-mediated dUTP Nick-End Labeling (TUNEL) assay. The cellular levels of malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) were analyzed by enzyme linked immune-sorbent assays (ELISA), and reactive oxygen species (ROS) levels using dichlorodihydrofluorescin diacetate (DCFH) staining. Quantitative RT-PCR and Western blotting were respectively used to analyze the expression levels of specific mRNAs and proteins. HUVECs were transfected with Nrf2 siRNA to induce knockdown of the latter. Key findings: Euxanthone pre-treatment rescued the HUVECs from ox-LDL-induced cytotoxicity, apoptosis and DNA fragmentation in a dose-dependent manner. In addition, euxanthone also significantly reversed ox-LDL-triggered loss of mitochondrial membrane potential (MMP), cytochrome C release from mitochondria to cytosol, cleavage of caspase-3 and PARP, and increase in Bax/Bcl-2 ratio. Pre-treatment with euxanthone markedly suppressed ox-LDL-induced ROS generation and inhibition of antioxidant enzymes, as well as the up-regulation of pro-inflammatory factors like MCP-1, IL-1β and TNF-α in the HUVECs. Euxanthone up-regulated and activated Nrf2 by repressing Keap1, and increased the expression of its downstream genes HO-1 and NQO-1. Nrf2 knockdown abrogated the cyto-protective, anti-apoptotic, anti-oxidant and anti-inflammatory effects of euxanthone in ox-LDL-treated HUVECs. Finally, euxanthone activated Nrf2 via the MAPK pathway and blocking the latter likewise negated the protective effects of euxanthone against cell ox-LDL. Significance: Euxanthone protected HUVECs against the oxidative and inflammatory damage induced by ox-LDL, indicating its potential as a novel therapeutic agent for AS. 

Retracted: Yes

PubPeer comments:
 - RE: M. Benn, G. F. Watts, A. Tybjaerg-Hansen and B. G. Nordestgaard,  Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication, vol. 97, no. 11, pp. 3956-3964, 2012. The prevalence of 1 137 for familial hypercholesterolemia was declared to be an error in 2013 [1] and 2014 [2]. The migration of this error through FH literature is partly due to the way the corrections were published. -tThe original 2013 Correction was buried in a caption to an illustration: https: pubpeer.com publications 2407D5512D3D374551C84227D66A66. -tThe official 2014 Corrigendum was not sufficiently promoted and is equivocal: https: pubpeer.com publications D69DE2E1620A86BE30004C0E458326. References [1] tB. G. Nordestgaard, M. J. Chapman, S. E. Humphries, H. N. Ginsberg, L. Masana, O. S. Descamps, O. Wiklund, R. A. Hegele, F. J. Raal, J. C. Defesche, A. Wiegman, R. D. Santos, G. F. Watts, K. G. Parhofer and others,  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society, vol. 34, no. 45, pp. 3478-3490, 2013. [2] tM. Benn, G. F. Watts, A. Tybjaerg-Hansen and B. G. Nordestgaard,  Corrigendum: Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication, vol. 99, no. 12, pp. 4758-4759, 2014. ,